MeMed Severity™ has received FDA Breakthrough Device Designation as a host-response test designed to predict severe outcomes up to 72 hours and mortality 14 days in advance in patients with acute ...

Newark, NJ, Sept. 10, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global capillary and venous blood sampling market is expected to grow from USD 1.5 billion in 2019 and ...

A new needle-free blood test, TAP, launched by UHMBT NHS Trust, transforms care for patients with learning disabilities or needle phobia ...

As COVID-19 seems to be making a comeback in many areas of the world, including Japan, a new study published on the preprint server medRxiv* in October 2020 shows the relevance of microsamples of ...

BOSTON, July 31, 2024 /PRNewswire/ -- O'Ryan.Health, a leader in at-home pediatric healthcare innovation, today announced it has become the first US company to launch two, parent-led observational ...